Evidence map›Paper›PMID 37303632›Full record

ArticleAmerican journal of translational research2023

Integrative bioinformatics and RNA sequencing based methodology results in the exploration of breast invasive carcinoma biomarkers.

Qiang Zhu, Luyan Zhang, Faisal Mahmood Sadiq, Mostafa A Abdel-Maksoud, Saeedah Musaed Almutairi, Wahidah H Al-Qahtani, Jaweria Gul, Muhammad Jamil, Isha Fatima, Sikandar Zia

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Qiang ZhuDepartment of Breast Surgery, Beijing Tiantan Hospital, Capital Medical University No. 119 South Fourth Ring West Road, Fengtai District, Beijing 100070, The People's Republic of China.
Luyan ZhangDepartment of Oncology, Binzhou People's Hospital Binzhou 256600, Shandong, The People's Republic of China.
Faisal Mahmood SadiqPunjab Institute of Mental Health Lahore, Pakistan.
Mostafa A Abdel-MaksoudDepartment of Botany and Microbiology, College of Science, King Saud University Riyadh P.O. 2455, Riyadh 11451, Saudi Arabia.
Saeedah Musaed AlmutairiDepartment of Botany and Microbiology, College of Science, King Saud University Riyadh P.O. 2455, Riyadh 11451, Saudi Arabia.
Wahidah H Al-QahtaniDepartment of Food Sciences & Nutrition, College of Food and Agricultural Sciences, King Saud University P.O. Box 270677, Riyadh 11352, Saudi Arabia.
Jaweria GulDepartment of Biotechnology, Shaheed Benazir Bhutto University Sheringal, Dir Upper, Pakistan.
Muhammad JamilPARC Arid Zone Research Center Dera Ismail Khan, Pakistan.
Isha FatimaAkhtar Saeed Medical and Dental College Lahore, Pakistan.
Sikandar ZiaDepartment of Biochemistry, Gajju Khan Medical College Swabi, Pakistan.
Farooq Hospital · PKShaheed Benazir Bhutto University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreviously reported breast invasive carcinoma (BRIC) biomarkers have compromised utility because of their heterogeneity-specific behaviors. The goal of this study was to find BRIC biomarkers that could be used in spite of the heterogeneity barrier.

methodsPreviously reported BRIC-linked hub genes were obtained from the literature via a search technique. A protein-protein interaction (PPI) network of the extracted hub genes was constructed, visualized, and analyzed to explore the top six real hub genes. Following this, real hub genes' expression profiling was carried out using various TCGA data sources and RNA sequencing (RNA-seq) of BT 20 and HMEC cell lines to uncover the tumor-driver roles of the real hub genes.

resultsIn total, 124 BRIC-linked hub genes were collected from the literature via the search technique. From these collected hub genes, a total of 6 genes, including Centrosomal protein of 55 kDa (CEP55), Kinesin Family Member 2C (KIF2C), kinesin family member 20A (KIF20A), Ribonucleotide Reductase Regulatory Subunit M2 (RRM2), Aurora A Kinase (AURKA), and Protein Regulator of cytokinesis 1 (PRC1) were determined to be the real hub genes. Via expression profiling and validation analyses, we documented the overexpression of CEP55, KIF2C, KIF20A, RRM2, AURKA, and PRC1 real hub genes in BRIC patients with different clinical variables. Further correlational analyses showed diverse associations among real hub genes' expression and other important parameters, including promoter methylation status, genetic alteration, overall survival (OS), relapse-free survival (RFS), tumor purity, CD8+ T, CD4+ T immune cell infiltration, and different mutant genes across BRIC samples. Finally, in this work, we investigated several transcription factors (TFS), microRNAs, and therapeutic medicines related to the real hub genes that have great therapeutic potential.

conclusionIn conclusion, we discovered six real hub genes, which may be employed as novel potential biomarkers for BRIC patients with different clinical parameters.

Indexed as

biomarkerBRIChub genes

Identifiers

PMID37303632
PMCPMC10251034
OpenAlexW4380290635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.